Athanassios (Ethan) Argiris, MD

Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competin causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10(6):1956-1962, 2004.

Simon M, Argiris A, Murren JR. Progress in small cell lung cancer. Crit Rev Oncol Hematol 49(2):119-133, 2004.

Argiris A, Wang CX, Whalen SG, DiGiovanna MP. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10(4):1409-1420, 2004.

Argiris A, Li Y, Langer C, Murphy B, Forastiere AA. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22(2):262-268, 2004.

Charles L. Bennett, MD, PhD

Evens AM, Luminari S, Bennett CL. Epoetin-induced pure red cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group, Semin Hematol, in press, 2004.

Calhoun EA, Fishman DA, Lurain JR, Weishman EE, Bennett CL. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 93(1):164-169, 2004.

Sureka A, Parada JP, Deloria-Knoll M, Chmiel JS, Phan L, Lyons TM, Ali S, Yarnold PR, Weinstein RA, Dehovitz, JA, Jacobson JM, Goetz MD, Campo RE, Berland D, Bennett CL, Uphold CR. HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDs 18(2):99-107, 2004.

Bennett CL, Parisi MA, Eckert ML, Huynh HM, Chance PF, Glass IA. Joubert syndrome: a haplotype segregation strategy and exclusion of the zinc finger protein of cerebellum 1 (ZIC1) gene. Am J Med Genet 125A(2):117-124, 2004.

De la Lande IS, Siebert TE, Bennett CL, Stafford I, Horowitz JD. Influence of the endothelium on ex vivo tolerance and metabolism of glyceryl trinitrate in rat aorta. Eur J Pharmacol 486(2):201-207, 2004.

Uphold CR, Deloria-Knoll M, Palella FJ Jr., Parada JP, Chmiel JS, Phan L, Bennett CL. US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. Chest 125(2):548-556, 2004.

Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, Kwaan HC, McCoy JM, Schmitt BP, Davidson CJ, Yarnold PR, Gorelick PB, Bennett CL. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35(2):533-537, 2004.

Adams JR, Elting LS, Lyman GH, George NJ, Lembersky BC, Armitage JO, Demetri GD, Bennett CL. Use of erythropoietin in cancer patients: assessment of oncologists’ practice patterns in the United States and other countries. Am J Med 116(1):28-34, 2004.

 Al B. Benson III, MD

Benson AB III, Catalano PJ. A rose is a rose is a rose…or not. J Clin Oncol 2004.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brand D, O’Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB III, Fuchs CS. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22(4):648-657, 2004.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O’Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB III, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected cancer: findings from the Intergroup 0114 Study. J Clin Oncol 22(1):166-174, 2004.

 Lisa N. Boggio, MD

Boggio L, Green D. Coagulopathies associated with lymphoproliferative disorders. Curr Hematol Rep 3(1):1-4, 2004.

Raymond C. Bergan, MD

Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Stadler WM, Vogelzang NJ, Teh BT.  Gene expression profiling of renal medullary carcinoma:  potential clinical relevance.  Cancer 100(5):976-985, 2004.

James F. Brandman, MD

Elizabeth A. Eklund, MD

Sandgren S, Wittrup A, Cheng F, Jonsson M, Eklund E, Busch S, Belting M. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004 [Epub ahead of print]

Andrew M. Evens, DO

Evens AM, Gordon LI. The Ghobial/Witzig paper revisited: radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology, in press, 2004.

Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell tranplantation: the problem of iron and oxidative stress. Bone Marrow Transplant, in press, 2004.

Evens AM, Gordon LI. Radioimmunotherapy in non-Hodgkin's lymphoma: the Zevalin trials and beyond. Clinical Lymphoma, in press, 2004.

Evens AM, Luminari S, Bennett CL. Epoetin-induced pure red cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group, Semin Hematol, in press, 2004.

Evens AM, Gartenhaus RB. Treatment of mature T-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol, in press, 2004.

Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in combination therapy. Leuk Res, in press, 2004.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB. Imexon-induced apoptosis in multiple myeloma cells is caspase-8 dependent. Clin Cancer Res 10(4):1481-1491, 2004.

 Ronald B. Gartenhaus, MD

Evens AM, Gartenhaus RB. Treatment of mature T-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol, in press, 2004.

Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in combination therapy. Leuk Res, in press, 2004.

Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28(5):429-442, 2004.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB. Imexon-induced apoptosis in multiple myeloma cells is caspase-8 dependent. Clin Cancer Res 10(4):1481-1491, 2004.

Leo I. Gordon, MD

Evens AM, Gordon LI. The Ghobial/Witzig paper revisited: radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology, in press, 2004.

Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell tranplantation: the problem of iron and oxidative stress. Bone Marrow Transplant, in press, 2004.

Evens AM, Gordon LI. Radioimmunotherapy in non-Hodgkin's lymphoma: the Zevalin trials and beyond. Clinical Lymphoma, in press, 2004.

Verma A, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 33(7):715-719, 2004.

Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubitschek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long term follow-up of a phase I/II study. Blood 103(12):4429-4431, 2004.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB. Imexon-induced apoptosis in multiple myeloma cells is caspase-8 dependent. Clin Cancer Res 10(4):1481-1491, 2004.

Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33(2):161-164, 2004.

 William J. Gradishar, MD

Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW Jr. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22(6):1071-1077, 2004.

David Green, MD

McDermott MM, Greeland P, Guralnik JM, Ferrucci L, Green D, Liu K, Criqui MH, Schneider JR, Chan C, Ridker P, Pearce WH, Martin G, Clark E, Taylor L. Inflammatory markers, d-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. Vascular Med, in press, 2004.

Kearon C, Geerts W, Demers C, Green D. Comparison of one month with three months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost, in press, 2004.

Tallman MS, Lefebvre P, Baine R, Shoji M, Cohen I, Green D, Kwaan H, Paietta, Rickles FR. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Pathophysiol Haemost Thromb, in press, 2004.

Lefebvre P, Velasco PT, Dear A, Lounes KC, Lord ST, Brennan SO, Green D, Lorand L. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen A[[alpha]]IVS4+1 G>T mutation and an A[[alpha]]Gln328 truncation (Fibrinogen Keokuk). Blood 103(7):2571-2576, 2004.

Rosenson RS, Wolff D, Green D, Boss AH, Kensey KR. Aspirin. Aspirin does not alter native blood viscosity [Research letter]. J Thromb Haemost 2(2):340-341, 2004.

Boggio L, Green D. Coagulopathies associated with lymphoproliferative disorders. Curr Hematol Rep 3(1):1-4, 2004.

Virginia G. Kaklamani, MD

Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T. TGFBR1*6A and cancer: a meta-analysis of 12 case-controlled studies. J Clin Oncol 22(4):756-758, 2004.

Timothy M. Kuzel, MD

Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM. Comparison of selective retinoic acid receptor—and retinoic X receptor—mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol, in press, 2004.

Hau C. Kwaan, MD

Tallman MS, Lefebvre P, Baine R, Shoji M, Cohen I, Green D, Kwaan H, Paietta, Rickles FR. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Pathophysiol Haemost Thromb, in press, 2004.

Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J. Thromb Haemost 2(2):306-312, 2004.

Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, Kwaan HC, McCoy JM, Schmitt BP, Davidson CJ, Yarnold PR, Gorelick PB, Bennett CL. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35(2):533-537, 2004.

Richard C. Meagher, PhD

Jayesh Mehta, MD

Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell tranplantation: the problem of iron and oxidative stress. Bone Marrow Transplant, in press, 2004.

Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004 [Epub ahead of print]

Verma A, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 33(7):715-719, 2004.

Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, van Rhee F, DeRienzo S, O’Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33(4):389-396, 2004.

Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33(2):161-164, 2004.

Mary F. Mulcahy, MD

Golf M, Paice J, Feulner E, O’Leary C, Marcotte S, Mulcahy M. Case discussion in palliative medicine: status epilepticus. J Palliat Med 7(1):85-88, 2004.

Hidayatullah Munshi, MD

Wu Yi, Munshi HG, Sen R, Snipas SJ, Salvesen GS, Fridman R, Stack MS. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Cem 279(9):8287-8289, 2004.

Judith A. Paice, PhD, RN

Bines A, Paice JA. Institutional change in pain control. Nursing, in press, 2004.

Paice JA. Outcome measures in interventional pain management. Pain Digest, in press, 2004.

Paice JA. Assessment of symptom clusters in persons with cancer. J Natl Cancer Inst, in press, 2004.

Ferrini R, Paice J. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2(1):90-94, 2004.

Paice JA, Muir JC, Shott S. Palliative care at the end of life: comparing quality in diverse settings. Am J Hospice Palliat Med 21(1):19-27, 2004.

Golf M, Paice J, Feulner E, O’Leary C, Marcotte S, Mulcahy M. Case discussion in palliative medicine: status epilepticus. J Palliat Med 7(1):85-88, 2004.

Boris Pasche, MD, PhD

Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T. TGFBR1*6A and cancer: a meta-analysis of 12 case-controlled studies. J Clin Oncol 22(4):756-758, 2004.

Pasche B, Serhan CN. Is C-reactive protein an inflammation opsonin that signals colon cancer risk? JAMA 291(5):623-623, 2004.

Jyoti D. Patel, MD

Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 291(14):1763-1768, 2004.

Leonidas C. Platanias, MD, PhD

Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC. Role of the p38 map kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL expressing cells. J Biol Chem 2004 [Epub ahead of print]

Lekmine F, Sassano A, Uddin S, Smith J, Majchrzak B, Brachmann SM, Hay N, Fish EN, Platanias LC. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 295(1):173-182, 2004.

Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanias LC. Role of p38alpha Map kinase in Type 1 interferon signaling. J Biol Chem 279(2):970-979, 2004.

Steven T. Rosen, MD

Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM. Comparison of selective retinoic acid receptor—and retinoic X receptor—mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol, in press, 2004.

Seema Singhal, MD

Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004 [Epub ahead of print]

Verma A, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 33(7):715-719, 2004.

Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, van Rhee F, DeRienzo S, O’Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33(4):389-396, 2004.

Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33(2):161-164, 2004.

Gerald A. Soff, MD

Wang H, Schultz R, Hong J, Cundiff DJ, French E, Jiang K, Soff GA. Cell-surface-dependent generation of angiostatin4.5. Cancer Res 64(1):162-168, 2004.

Martin S. Tallman, MD

Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in combination therapy. Leuk Res, in press, 2004.

Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC. Role of the p38 map kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL expressing cells. J Biol Chem 2004 [Epub ahead of print]

Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogs in and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28(5):429-442, 2004.

Verma A, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 33(7):715-719, 2004.

Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, Dewald G, Rowe JM, Wiernik Ph, Tallman MS, Look AT. Activating FLT3 mutations in CD117/KIT positive T-cell acute lymphoblastic leukemias. Blood 2004 [Epub ahead of print]

Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100(7):1449-1458, 2004.

Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22(6):1078-1086, 2004.

Tallman MS, Kim HT, Paietta E, Bennett JM, Dewald G. Cassileth PA, Wiernik PH, Rowe JM. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol 22(7):1276-1286, 2004.

Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH. A phase III study of three induction regimens and of priming with G-CSF older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103(2):479-485, 2004.

Jamie H. Von Roenn, MD

Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol 22(8):1491-1500, 2004.

Sigmund A. Weitzman, MD

Panduri V, Weitzman SA, Chandel NS, Kamp DW. Mitochondrial-derived free radicals mediate asbestos-induced alveolar epithelial cell apoptosis. Am J Physiol Lung Cell Mol Physiol 2004 [Epub ahead of print]

Jane N. Winter, MD

Verma A, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 33(7):715-719, 2004.

Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33(2):161-164, 2004.

Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res 28(5):537-540, 2004.